1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health and behavioural conditions
  5. Psychosis and schizophrenia

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

Technology appraisal guidance [TA213] Published date: 26 January 2011

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submissions
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • Appendix A: Appraisal Committee members, guideline representatives and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that aripiprazole is recommended as an option for treating schizophrenia. Additional minor maintenance update also carried out.

March 2012: minor maintenance

  • National Institute for Health and Care Excellence (NICE)

  • Next